Cardioprotection by a nonerythropoietic, tissue-protective peptide mimicking the 3D structure of erythropoietin
- 26 July 2010
- journal article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 107 (32) , 14357-14362
Abstract
Erythropoietin (EPO), originally identified for its critical hormonal role in regulating production and survival of erythrocytes, is a member of the type 1 cytokine superfamily. Recent studies have shown that EPO has cytoprotective effects in a wide variety of tissues, including the heart, by preventing apoptosis. However, EPO also has undesirable effects, such as thrombogenesis. In the present study, we investigated whether a helix B-surface peptide (HBSP), a nonerythropoietic, tissue-protective peptide mimicking the 3D structure of erythropoietin, protects cardiomyocytes from apoptosis in vitro and in vivo. In cultured neonatal rat cardiomyocytes, HBSP clearly inhibited apoptosis (≈80%) induced by TNF-α, which was comparable with the effect of EPO, and activated critical signaling pathways of cell survival, including Akt, ERK1/2, and STAT3. Among these pathways, Akt was shown to play an essential role in HBSP-induced prevention of apoptosis, as assessed by using a small interfering RNA approach. In the dilated cardiomyopathic hamster (J2N-k), whose cardiac tissues diffusely expressed TNF-α, HBSP also inhibited apoptosis (≈70%) and activated Akt in cardiomyocytes. Furthermore, the levels of serum creatine kinase activity and of cardiac expression of atrial natriuretic peptide, a marker of chronic heart failure, were down-regulated in animals treated with HBSP. These data demonstrate that HBSP protects cardiomyocytes from apoptosis and leads to a favorable outcome in failing hearts through an Akt-dependent pathway. Because HBSP does not have the undesirable effects of EPO, it could be a promising alternative for EPO to treat cardiovascular diseases, such as myocardial infarction and heart failure.Keywords
This publication has 42 references indexed in Scilit:
- Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietinProceedings of the National Academy of Sciences, 2008
- Antiapoptotic properties of erythropoiesis-stimulating proteins in models of cisplatin-induced acute kidney injuryAmerican Journal of Physiology-Renal Physiology, 2008
- Systemically delivered Erythropoietin transiently enhances adult hippocampal neurogenesisJournal of Neurochemistry, 2007
- Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activitiesProceedings of the National Academy of Sciences, 2006
- Erythropoietin, Modified to Not Stimulate Red Blood Cell Production, Retains Its Cardioprotective PropertiesThe Journal of Pharmacology and Experimental Therapeutics, 2006
- Cardioprotection afforded by NF-κB ablation is associated with activation of Akt in mice overexpressing TNF-αAmerican Journal of Physiology-Heart and Circulatory Physiology, 2006
- EPO and α-MSH prevent ischemia/reperfusion-induced down-regulation of AQPs and sodium transporters in rat kidneyKidney International, 2004
- Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-α, in Patients With Moderate-to-Severe Heart FailureCirculation, 2003
- Activation of the transcription factor NF-κB by the erythropoietin receptorCellular Signalling, 2001
- Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death.Journal of Clinical Investigation, 1996